Skip to main content
. 2020 Mar 31;24(11):3923–3937. doi: 10.1007/s00784-020-03259-8

Fig. 8.

Fig. 8

Model for the effects of the two investigated HA formulations on the behavior and functionality of mesenchymal stromal ST2 and pre-osteoblastic MC3T3-E1 cells. Treatment of each of the two cell lines, used as a progenitor source of osteoblasts, with HA (a structural formula is presented) results in induced cellular proliferation and bone matrix production, as suggested by the upregulated expression of Col1a1, Col1a2, and Spp1 genes encoding bone matrix proteins. These effects are accompanied and likely influenced by induced TGF-β and FGF signaling in the HA-treated cells. Signaling through both BMP-induced Smad and Wnt pathways is strongly downregulated upon HA treatment, which results in inhibited progression of the osteogenic differentiation as evidenced by decreased expression of intermediate and late osteogenic differentiation marker genes such as Runx2, Bglap2, Ibsp, and Alpl. Finally, HA maintains the stemness of osteoprogenitors by inducing the expression of the transcription factor Sox2 and its direct targets Yap1 and Bmi1. Inhibited Wnt signaling and induced TGF-β/FGF signaling may contribute to the self-renewal capability of HA-treated osteoprogenitors. Taken together, our results suggest a prominent role of HA in inducing the growth, and maintaining the stemness and differentiation potential of mesenchymal stromal and pre-osteoblastic cells. Solid lines in the model represent direct evidence and common knowledge; dashed lines display links that are solidly supported by literature reports. For more details on the displayed links between the HA-induced functionalities, please refer to the text